Viatris Stock Forecast for 2023 - 2025 - 2030
Updated on 02/05/2023
Viatris Stock Forecast and Price Target
The average price target for Viatris's stock of $13.50 recently provided by eight leading analysts would represent a 10.84% upside from its last closing price if reached. This potential increase is based on a high estimate of $18.00 and a low estimate of $10.00. You may be interested in rivals even if you aren't interested in Viatris stock.
10.84% Upside
Viatris Fair Value Forecast for 2023 - 2025 - 2030
In the last two years, Viatris's Price has fallen from $19.09 to $15.98 – a 16.29% decrease. According to 8 prominent analysts, Viatris's Fair Value will fall by 7.03% in the next year, reaching $14.86. Over the next eight years, experts predict that Viatris's Fair Value will grow at a rate of 12.16%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
11
|
$164.61 | $181.05 | 9.65% |
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$339.08 | $333.19 | 17.97% |
| ABBV Stock Forecast | AbbVie | Outperform |
10
|
$145.20 | $162.12 | 13.64% |
| PFE Stock Forecast | Pfizer Inc | Outperform |
3
|
$44.06 | $53.97 | 19.50% |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
8
|
£10.58k | £153.20 | -98.53% |
Viatris Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Viatris's Revenue has grown by 55.53%, rising from $11.50B to $17.89B. According to 6 prominent analysts, Viatris's Revenue will fall by 7.01% in the next year, reaching $16.63B. By 2030, professionals believe that Viatris's Revenue will decrease by 4.39%, reaching $17.10B – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| NOVN Stock Forecast | Novartis | Hold |
10
|
CHF85.77 | CHF103.75 | 9.89% |
| BMY Stock Forecast | Bristol-Myers Squibb Co | Outperform |
2
|
$74.45 | $80.99 | 11.48% |
| AMGN Stock Forecast | Amgen Inc | Hold |
7
|
$245.17 | $268.00 | 13.39% |
Viatris Dividend per Share Forecast for 2023 - 2025 - 2030
Viatris's Dividend per Share has decreased In the last zero years, from $0.45 to $0.45 – a 0.00% drop. For next year, analysts predict Dividend per Share of $0.51, which would mean an increase of 13.33%. In 2030, professionals predict that Viatris's Dividend per Share will decrease by 100.00%, to $0.00.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$84.50 | $87.30 | 4.14% |
| REGN Stock Forecast | Regeneron Pharmaceuticals Inc | Outperform |
2
|
$722.13 | $796.73 | 8.29% |
| GSK Stock Forecast | GSK | Hold |
16
|
£1.44k | £16.95 | -98.88% |
Viatris Free Cash Flow Forecast for 2023 - 2025 - 2030
Viatris's Free Cash Flow has grown In the last two years, rising from $1.59B to $2.56B – a growth of 60.94%. In the next year, analysts believe that Free Cash Flow will reach $3.62B – an increase of 41.35%. For the next eight years, experts predict that Viatris's Free Cash Flow will grow at a rate of 61.12%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| 4568 Stock Forecast | Daiichi Sankyo Company | Outperform |
18
|
¥4.07k | ¥0.00 | 35.30% |
| BAYN Stock Forecast | Bayer | Outperform |
7
|
56.68€ | 74.54€ | 33.20% |
| RKT Stock Forecast | Reckitt Benckiser Group | Outperform |
16
|
£5.81k | £68.33 | -98.85% |
Viatris Net Income Forecast for 2023 - 2025 - 2030
In the last two years, Viatris's Net Income has seen a drop from $16.80M to $-1.27B – a 7654.17% decrease. According to 6 major analysts, Viatris's Net Income will fall by 427.08% in the next year, reaching $4.15B. Professionals believe that By 2030, Viatris's Net Income will fall to $5.08B– a 500.13% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| ALC Stock Forecast | Alcon | Outperform |
15
|
CHF66.18 | CHF0.00 | 30.51% |
| HZNP Stock Forecast | Horizon Therapeutics Public | Buy |
16
|
$113.00 | $0.00 | 23.89% |
| 4503 Stock Forecast | Astellas Pharma | Outperform |
18
|
¥1.92k | ¥0.00 | 24.74% |
Viatris EBITDA Forecast for 2023 - 2025 - 2030
Viatris's EBITDA has seen impressive growth In the last two years, rising from $3.26B to $6.18B – a growth of 89.55%. According to 6 analysts, Viatris's EBITDA will fall by 3.11% in the next year, reaching $5.99B. For the next eight years, the forecast is for EBITDA to grow by 16.31%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| BAX Stock Forecast | Baxter International | Outperform |
17
|
$46.68 | $62.83 | 24.25% |
| FRE Stock Forecast | Fresenius SE & Co. KGaA | Outperform |
18
|
27.11€ | 35.72€ | 19.88% |
| DIVISLAB Stock Forecast | Divi's Laboratories | Hold |
18
|
Rp3.43k | Rp5.23k | 42.86% |
Viatris EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Viatris's EBIT has grown by 108.66%, rising from $1.42B to $2.97B. For the next year, analysts predict that EBIT will reach $5.60B – an increase of 88.68%. Over the next eight years, experts believe that Viatris's EBIT will grow at a rate of 113.19%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| CIPLA Stock Forecast | Cipla | Outperform |
18
|
Rp1.08k | Rp1.05k | 1.08% |
| JAZZ Stock Forecast | Jazz Pharmaceuticals | Outperform |
14
|
$158.79 | $0.00 | 25.95% |
| 500124 Stock Forecast | Dr. Reddy's Laboratories | Outperform |
18
|
Rp4.27k | Rp5.47k | 15.97% |
Viatris EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last two years, Viatris's EPS has fallen from $4.42 to $3.70 – a 16.29% decrease. According to 8 prominent analysts, Viatris's EPS will fall by 7.03% in the next year, reaching $3.44. Over the next eight years, experts predict that Viatris's EPS will grow at a rate of 12.16%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| CTLT Stock Forecast | Catalent | Outperform |
15
|
$56.05 | $76.00 | 30.24% |
| GRF Stock Forecast | Grifols | Outperform |
18
|
13.65€ | 27.25€ | 55.31% |
| PRGO Stock Forecast | Perrigo | Buy |
16
|
$37.20 | $47.75 | 27.69% |